<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799157</url>
  </required_header>
  <id_info>
    <org_study_id>250-12951-201</org_study_id>
    <nct_id>NCT05799157</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts</brief_title>
  <official_title>Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veradermics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veradermics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study has been designed to determine the safety and efficacy of repeated&#xD;
      treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle&#xD;
      control patch in subjects with verruca vulgaris&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol 250-12951-201 is a planned Phase 2 study entitled &quot;A Multi-Center, Randomized,&#xD;
      Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with&#xD;
      Verruca Vulgaris&quot;. Eligible subjects will be randomized into one of the three treatment&#xD;
      groups (high dose, low dose, vehicle).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2023</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period</measure>
    <time_frame>Baseline up to Day 134</time_frame>
    <description>Complete clinical resolution is defined as the target lesion with area = 0.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Proportion of subjects with complete clinical resolution of Target Lesion by visit</measure>
    <time_frame>Days 22, 43, 64, 85, 106, and 134</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects with complete clinical resolution of all the Non-Target Lesion(s) by visit</measure>
    <time_frame>Days 22, 43, 64, 85, 106, and 134</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Verruca Vulgaris</condition>
  <condition>Warts</condition>
  <condition>Common Wart</condition>
  <arm_group>
    <arm_group_label>Treatment Group A (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C (Vehicle)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VDMN-21 Patch Low Dose</intervention_name>
    <description>Microneedle patch containing 125 mcg of active drug</description>
    <arm_group_label>Treatment Group A (Low Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VDMN-21 Patch High Dose</intervention_name>
    <description>Microneedle patch containing 250 mcg of active drug</description>
    <arm_group_label>Treatment Group B (High Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Patch</intervention_name>
    <description>Placebo microneedle patch containing no active drug (i.e., placebo)</description>
    <arm_group_label>Treatment Group C (Vehicle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a male or non-pregnant female, 18 to 65 years of age.&#xD;
&#xD;
          -  Subject has provided written informed consent/assent.&#xD;
&#xD;
          -  Females must be post-menopausal, surgically sterile, or use an effective method of&#xD;
             birth control. Women of childbearing potential (WOCBP) must have a negative urine&#xD;
             pregnancy test (UPT) at Visit 1/Baseline.&#xD;
&#xD;
          -  Subject has at least 1 and up to 8 common warts (verruca vulgaris),&#xD;
&#xD;
          -  Subject is willing to undergo test article therapy as directed, comply with study&#xD;
             instructions (including availability to a smart phone or equivalent device for&#xD;
             telehealth visit requirements), and commit to all follow-up visits for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Subject is in good general health and free of any disease state or physical condition&#xD;
             that might impair evaluation of the identified warts and/or treatment area or exposes&#xD;
             the subject to an unacceptable risk by study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
          -  Subject has received a Human Papilloma Virus (HPV) vaccine within 24 weeks of&#xD;
             Baseline.&#xD;
&#xD;
          -  Subject used or will use oral zinc and/or cimetidine within 30 days prior to&#xD;
             enrollment or during the course of the study.&#xD;
&#xD;
          -  Subject has received 3 or more prior treatments to the Target Lesion without&#xD;
             resolution.&#xD;
&#xD;
          -  Subject received any of the following therapies within the specified wash-out period&#xD;
             prior to Baseline in the treatment area of the Target Lesion&#xD;
&#xD;
               1. LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL],&#xD;
                  PDT; 12 weeks&#xD;
&#xD;
               2. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester [SADBE], etc.),&#xD;
                  retinoids, hydrogen peroxide; 12 weeks&#xD;
&#xD;
               3. Cryotherapy, biopsy, electrodessication, curettage, antimetabolite therapy (e.g.,&#xD;
                  5- fluorouracil), cantharidin, or any other treatment that in the opinion of the&#xD;
                  Investigator may affect the Target Lesion; 6 weeks&#xD;
&#xD;
               4. Over-the-counter (OTC) wart therapies, paring Â± occlusion; 1 week&#xD;
&#xD;
          -  Subject has scars, tattoos, or other features that may interfere with the evaluation&#xD;
             of the Target Lesion, in the opinion in the investigator.&#xD;
&#xD;
          -  Subject has a significant autoimmune condition or is immunocompromised based on their&#xD;
             medical condition (e.g., HIV, malignancy, etc.), medication use, or other factors.&#xD;
             Routine use of inhaled, intranasal or ophthalmologic corticosteroids during the study&#xD;
             is allowed.&#xD;
&#xD;
          -  Subject has received systemic immunosuppressive therapy such as steroids,&#xD;
             methotrexate, cyclosporine, tacrolimus, chemotherapy, etc. within in 4 weeks prior to&#xD;
             Baseline.&#xD;
&#xD;
          -  Subject has any active malignancy or are undergoing treatment for any malignancy other&#xD;
             than nonmelanoma skin cancer;&#xD;
&#xD;
          -  Subject has history of significant ophthalmologic inflammatory disease, including&#xD;
             uveitis.&#xD;
&#xD;
          -  Subject is currently enrolled in an investigational drug, biologic, or device study.&#xD;
&#xD;
          -  Subject has used an investigational drug, investigational biologic, or investigational&#xD;
             device treatment within 30 days prior to Visit 1/Baseline.&#xD;
&#xD;
          -  Subject has a history of allergy or sensitivity to this antigen extract or similar&#xD;
             products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Weaver, MSCRM</last_name>
    <phone>520-965-7545</phone>
    <email>eweaver@therapeuticsinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

